Leonard Rickey Investment Advisors P.L.L.C. Acquires Shares of 312 Eli Lilly and Company (NYSE:LLY)

Leonard Rickey Investment Advisors P.L.L.C. bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 1st quarter, HoldingsChannel reports. The fund bought 312 shares of the company’s stock, valued at approximately $243,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cullinan Associates Inc. raised its holdings in shares of Eli Lilly and Company by 4.9% in the first quarter. Cullinan Associates Inc. now owns 6,628 shares of the company’s stock valued at $5,156,000 after purchasing an additional 309 shares during the last quarter. Iams Wealth Management LLC purchased a new stake in Eli Lilly and Company in the 1st quarter valued at about $311,000. tru Independence LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $201,000. Capstone Capital LLC bought a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $265,000. Finally, Edmonds Duncan Registered Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 6.9% during the first quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 849 shares of the company’s stock valued at $660,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.8 %

Shares of NYSE:LLY opened at $906.71 on Wednesday. The firm has a fifty day moving average price of $818.06 and a two-hundred day moving average price of $743.26. The company has a market cap of $861.75 billion, a price-to-earnings ratio of 133.54, a PEG ratio of 1.97 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a one year low of $434.34 and a one year high of $916.83.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.62 EPS. Analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the transaction, the insider now directly owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The disclosure for this sale can be found here. Insiders have sold 849,894 shares of company stock worth $727,475,118 over the last ninety days. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on LLY shares. Citigroup upped their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Truist Financial reissued a “buy” rating and set a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Argus boosted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.